AKBA Quote, Financials, Valuation and Earnings

Cellectar Biosciences has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.

Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1582.5%. Given that Cellectar Biosciences has higher upside potential than Akebia Therapeutics, analysts believe Cellectar Biosciences is more attractive than Akebia Therapeutics.

Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.963, suggesting its less volatile than the S&P 500 by 3.676%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Cellectar Biosciences quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Cellectar Biosciences's net income of -$14.7M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 730.55x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Lifeward has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -202.49%. Akebia Therapeutics's return on equity of -- beat Lifeward's return on equity of -81.96%.

Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Lifeward has an analysts' consensus of $9.00 which suggests that it could grow by 466.04%. Given that Lifeward has higher upside potential than Akebia Therapeutics, analysts believe Lifeward is more attractive than Akebia Therapeutics.

Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Lifeward has a beta of 1.732, suggesting its more volatile than the S&P 500 by 73.212%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Lifeward quarterly revenues of $7.5M. Akebia Therapeutics's net income of -$22.8M is lower than Lifeward's net income of -$15.3M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.54x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

Seres Therapeutics has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Seres Therapeutics's return on equity of --.

Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Seres Therapeutics has an analysts' consensus of $3.82 which suggests that it could grow by 418.23%. Given that Seres Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe Seres Therapeutics is more attractive than Akebia Therapeutics.

Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Seres Therapeutics has a beta of 2.186, suggesting its more volatile than the S&P 500 by 118.578%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Seres Therapeutics pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Seres Therapeutics quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Seres Therapeutics's net income of -$15.6M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Seres Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.93x for Seres Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -49.65%. Akebia Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Akebia Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Akebia Therapeutics is more attractive than NovaBay Pharmaceuticals.

Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $46.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Akebia Therapeutics's net income of -$22.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.